Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZD6912
- Development stage
- Phase 1
- Lead developer
- AstraZeneca
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules
- Administration
- Subcutaneous
01
Overview
AZD6912 is a small interfering RNA (siRNA) therapeutic developed by AstraZeneca for the treatment of rheumatoid arthritis. It specifically targets and inhibits the expression of complement factor B (CFB), a key component in the alternative pathway of the complement system, which plays a role in inflammatory processes. Preclinical studies demonstrated that AZD6912 effectively reduces hepatic CFB mRNA and serum CFB protein levels, leading to suppression of alternative pathway activity and reduction in articular inflammation and damage. The drug is administered subcutaneously and is currently being evaluated for safety, tolerability, pharmacokinetics, and pharmacodynamics in Phase 1 clinical trials involving healthy participants[1][2][3][4][5][7][9].
02
Targets
CFB (Complement Factor B)
Beyond the preview
Go deeper on AZD6912.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZD6912.